🇺🇸 FDA
Pipeline program

Pirfenidone Solution for Inhalation

AP01-005

Phase 2 small_molecule active

Quick answer

Pirfenidone Solution for Inhalation for Interstitial Lung Diseases (ILD), including but not limited to idiopathic pulmonary fibrosis (IPF) is a Phase 2 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Interstitial Lung Diseases (ILD), including but not limited to idiopathic pulmonary fibrosis (IPF)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials